Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Retirement Systems of Alabama

Retirement Systems of Alabama raised its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 26.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 530,022 shares of the company’s stock after acquiring an additional 112,286 shares during the period. Retirement Systems of Alabama owned approximately 0.07% of Roivant Sciences worth $6,116,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of ROIV. Gladius Capital Management LP acquired a new stake in shares of Roivant Sciences in the third quarter valued at approximately $35,000. nVerses Capital LLC purchased a new stake in Roivant Sciences in the 2nd quarter valued at $34,000. US Bancorp DE increased its stake in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after acquiring an additional 1,948 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Roivant Sciences during the 2nd quarter worth $36,000. Finally, Quarry LP acquired a new position in shares of Roivant Sciences during the 2nd quarter valued at about $53,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of ROIV opened at $11.69 on Thursday. The stock has a market cap of $8.51 billion, a PE ratio of 2.07 and a beta of 1.25. Roivant Sciences Ltd. has a 1-year low of $9.69 and a 1-year high of $13.06. The firm has a 50-day simple moving average of $11.92 and a two-hundred day simple moving average of $11.48.

Analyst Ratings Changes

ROIV has been the subject of a number of analyst reports. Bank of America upped their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $17.93.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total value of $1,132,000.00. Following the completion of the transaction, the chief operating officer now owns 606,525 shares of the company’s stock, valued at $6,865,863. This trade represents a 14.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Matthew Gline sold 1,983,257 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the completion of the transaction, the chief executive officer now owns 17,870,543 shares of the company’s stock, valued at approximately $210,693,701.97. This trade represents a 9.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,677,309 shares of company stock worth $43,283,184 over the last ninety days. Company insiders own 7.90% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.